Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

548
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
548
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

191
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
191

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incident heart failure is common and underrecognized in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease.

European journal of heart failure·2025
Same author

A Novel Transaortic Pulsatile Pump to Unload the Left Ventricle.

JACC. Basic to translational science·2025
Same author

Changes in Stressed Blood Volume With Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: The REBALANCE-HF Trial.

Journal of cardiac failure·2025
Same author

Real-World Analysis of Health Care Utilization With Baroreflex Activation Therapy for Heart Failure.

Journal of cardiac failure·2025
Same author

Cardiovascular Efficacy and Safety of Finerenone: A Meta-Analysis of Randomized Controlled Trials.

Clinical cardiology·2025
Same author

Cerebral Blood Flow in Orthostatic Intolerance.

Journal of the American Heart Association·2025
Same journal

Minimally invasive approaches to coronary artery bypass grafting: techniques, current evidence, and future directions.

Current opinion in cardiology·2026
Same journal

Advances in artificial intelligence for the evaluation of mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Role of nutritional interventions to reduce cardiometabolic disease burden in the community.

Current opinion in cardiology·2026
Same journal

Artificial intelligence for right ventricular assessment: current evidence and future directions.

Current opinion in cardiology·2026
Same journal

Coronary physiology and intravascular imaging in surgical and percutaneous revascularization.

Current opinion in cardiology·2026
Same journal

From sleep disorders to social determinants - risk predictors for cardiovascular diseases beyond low density lipoprotein cholesterol.

Current opinion in cardiology·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K

Device therapy for heart failure management.

Fouad Chouairi1, Allison Levin2, Marat Fudim2,3,4

  • 1Department of Medicine.

Current Opinion in Cardiology
|August 7, 2024
PubMed
Summary
This summary is machine-generated.

Cardiologists must stay updated on new heart failure (HF) device therapies. Emerging devices offer innovative treatments, including options for heart failure with preserved ejection fraction (HFpEF).

More Related Videos

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.2K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

Related Experiment Videos

Last Updated: Jun 17, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K
Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.2K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Medical Devices

Background:

  • Heart failure (HF) is a prevalent condition requiring interdisciplinary management.
  • Device therapy for HF is rapidly evolving, necessitating physician awareness.

Purpose of the Study:

  • To provide a practical overview of current and emerging device-based therapies for heart failure.
  • To highlight the importance of understanding these devices for cardiologists.

Main Methods:

  • Review of current literature on device development for HF.
  • Categorization of devices based on their therapeutic targets and mechanisms of action.

Main Results:

  • A diverse range of HF devices are in development, targeting various pathophysiological aspects.
  • Innovations include remote monitoring, interatrial shunts, left ventricular structural modification, and autonomic nervous system modulation.
  • Novel devices are emerging for heart failure with preserved ejection fraction (HFpEF).

Conclusions:

  • There has been significant growth in device-based HF treatments.
  • Physicians need to be knowledgeable about the mechanisms and applications of these new devices.